Fig. 6
From: Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Anti-tumour activity of DA+CHOEP combination in xenograft models of T-cell lymphoma. a, b NOD/SCID mice were subcutaneously inoculated with HD-MAR-2 (a) or OCI-Ly12 cells (b). When tumour nodules reached 150–200 mm3, they were randomised to receive treatment with DA, CHOEP, DA+CHOEP or vehicle (ctrl) as described in the Methods section. The beginning of the treatment is indicated by the black arrow. The data are expressed as the mean ± SEM. Asterisks indicate statistically significant differences (*p < 0.05; **p < 0.01; ***p < 0.001: ns: not significant). For each time point, the first asterisk refers to the DA-DA+CHOEP comparison, the second one to CHOEP-DA+CHOEP. c Representative images of CD-31 immunostaining of OCI-Ly12 tumours excised at day 21. Left panel, original magnification 40×. Right panel, quantification of blood vessel number/field, calculated of ten randomly selected fields of each section
